Compare CCU & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCU | AAPG |
|---|---|---|
| Founded | 1850 | 2009 |
| Country | Chile | China |
| Employees | N/A | 767 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2001 | N/A |
| Metric | CCU | AAPG |
|---|---|---|
| Price | $11.45 | $22.99 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $12.00 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 143.6K | 1.9K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.42 | $290.34 |
| Revenue Next Year | $4.71 | N/A |
| P/E Ratio | $18.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.71 | $20.11 |
| 52 Week High | $15.57 | $48.45 |
| Indicator | CCU | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 45.42 |
| Support Level | $10.71 | $23.15 |
| Resistance Level | $12.49 | $25.23 |
| Average True Range (ATR) | 0.37 | 0.41 |
| MACD | -0.04 | -0.35 |
| Stochastic Oscillator | 19.24 | 30.96 |
United Breweries Co Inc is a multi-category beverage company with operations in Chile, Argentina, Bolivia, Colombia, Paraguay and Uruguay. The company is a player in each one of the beverage categories in which it participates in Chile, including beer, soft drinks, mineral and bottled water, juice, wine, cider and pisco, among others. The Company has three operating segment with respect to its revenues in the geographic areas of commercial activity: Chile; International business and Wine. It generates maximum revenue from Chile.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.